All information products included in https://us-cert.cisa.gov/ics are provided "as is" for informational purposes only. The Department of Homeland Security (DHS) does not provide any warranties of any kind regarding any information contained within. DHS does not endorse any commercial product or service, referenced in this product or otherwise. Further dissemination of this product is governed by the Traffic Light Protocol (TLP) marking in the header. For more information about TLP, see https://us-cert.cisa.gov/tlp/.
1. EXECUTIVE SUMMARY
- CVSS v3 6.8
- ATTENTION: Low skill level to exploit
- Vendor: GE
- Equipment: Ultrasound Products
- Vulnerability: Protection Mechanism Failure
2. RISK EVALUATION
The affected GE Healthcare ultrasound devices utilize a method of software application implementation called “Kiosk Mode.” This Kiosk Mode is vulnerable to local breakouts, which could allow an attacker with physical access to gain access to the operating system of affected devices.
3. TECHNICAL DETAILS
3.1 AFFECTED PRODUCTS
The following versions of GE ultrasound products are affected:
- Vivid products, all versions
- LOGIQ, all versions, not including LOGIQ 100 Pro
- Voluson, all versions
- Versana Essential, all versions
- Invenia ABUS Scan station, all versions
- Venue, all versions, not including Venue 40 R1-3 and Venue 50 R4-5
3.2 VULNERABILITY OVERVIEW
A restricted desktop environment escape vulnerability exists in the Kiosk Mode functionality of affected devices. Specially crafted inputs can allow the user to escape the restricted environment, resulting in access to the underlying operating system.
- CRITICAL INFRASTRUCTURE SECTORS: Healthcare and Public Health
- COUNTRIES/AREAS DEPLOYED: Worldwide
- COMPANY HEADQUARTERS LOCATION: United States
This vulnerability was first reported to GE Healthcare by researchers Marc Ruef and Rocco Gagliardi of scip AG. Additional reports were provided to GE Healthcare by Michael Aguilar of Secureworks and Jonathan Bouman of Protozoan.nl.
GE Healthcare recommends organizations restrict physical access to devices by unauthorized individuals. Additionally, where available, GE recommends users enable the “system lock” password in the Administration GUI menu if possible. This will require a password to be entered before the system can be accessed. The ‘system lock’ would limit non-authenticated users from accessing the application.
GE recommends that users with questions reach out to a GE service representative and users with an active support account visit https://securityupdate.gehealthcare.com (login required).
CISA recommends users take defensive measures to minimize the risk of exploitation of this vulnerability. Specifically, users should:
- Ensure there is physical protections in place to prevent the devices from any unauthorized access.
- Encourage security awareness throughout the hospital staff to ensure clinical staff will report any unauthorized person trying to login or otherwise tamper with a medical device.
- Educate employees on social engineering, both online and in-person/on-site. This is often used to gain confidence to unauthorized resources.
- Where additional information is needed, refer to existing cybersecurity in medical device guidance issued by the FDA.
CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
CISA also provides a section for control systems security recommended practices on the ICS webpage on us-cert.gov. Several recommended practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
Additional mitigation guidance and recommended practices are publicly available on the ICS webpage on us-cert.gov in the Technical Information Paper, ICS-TIP-12-146-01B--Targeted Cyber Intrusion Detection and Mitigation Strategies.
Organizations observing any suspected malicious activity should follow their established internal procedures and report their findings to CISA for tracking and correlation against other incidents.
No known public exploits specifically target this vulnerability. This vulnerability is not exploitable remotely.
For any questions related to this report, please contact the CISA at:
Toll Free: 1-888-282-0870
CISA continuously strives to improve its products and services. You can help by choosing one of the links below to provide feedback about this product.
Please share your thoughts.
We recently updated our anonymous product survey; we'd welcome your feedback.